These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 9519948)

  • 21. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial.
    Calverley P; Pauwels R; Vestbo J; Jones P; Pride N; Gulsvik A; Anderson J; Maden C;
    Lancet; 2003 Feb; 361(9356):449-56. PubMed ID: 12583942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compliance during long-term treatment with fluticasone propionate in subjects with early signs of asthma or chronic obstructive pulmonary disease (COPD): results of the Detection, Intervention, and Monitoring Program of COPD and Asthma (DIMCA) Study.
    van Grunsven PM; van Schayck CP; van Deuveren M; van Herwaarden CL; Akkermans RP; van Weel C
    J Asthma; 2000 May; 37(3):225-34. PubMed ID: 10831147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial.
    Busse W; Wolfe J; Storms W; Srebro S; Edwards L; Johnson M; Bowers BW; Rogenes PR; Rickard K
    J Fam Pract; 2001 Jul; 50(7):595-602. PubMed ID: 11485708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma. International Study Group.
    Barnes NC; Marone G; Di Maria GU; Visser S; Utama I; Payne SL
    Eur Respir J; 1993 Jun; 6(6):877-85. PubMed ID: 8339809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma.
    Gustafsson P; Tsanakas J; Gold M; Primhak R; Radford M; Gillies E
    Arch Dis Child; 1993 Aug; 69(2):206-11. PubMed ID: 8215522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group.
    Dahl R; Lundback B; Malo JL; Mazza JA; Nieminen MM; Saarelainen P; Barnacle H
    Chest; 1993 Nov; 104(5):1352-8. PubMed ID: 8222787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of inhaled fluticasone propionate chlorofluorocarbon in 2- to 4-year-old patients with asthma: results of a double-blind, placebo-controlled study.
    Wasserman RL; Baker JW; Kim KT; Blake KV; Scott CA; Wu W; Faris MA; Crim C
    Ann Allergy Asthma Immunol; 2006 Jun; 96(6):808-18. PubMed ID: 16802768
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short- and long-term efficacy of fluticasone propionate in subjects with early signs and symptoms of chronic obstructive pulmonary disease. Results of the DIMCA study.
    van Grunsven P; Schermer T; Akkermans R; Albers M; van den Boom G; van Schayck O; van Herwaarden C; van Weel C
    Respir Med; 2003 Dec; 97(12):1303-12. PubMed ID: 14682412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
    Dransfield MT; Bourbeau J; Jones PW; Hanania NA; Mahler DA; Vestbo J; Wachtel A; Martinez FJ; Barnhart F; Sanford L; Lettis S; Crim C; Calverley PM
    Lancet Respir Med; 2013 May; 1(3):210-23. PubMed ID: 24429127
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of salmeterol versus doubling the dose of fluticasone propionate in patients with mild to moderate asthma.
    van Noord JA; Schreurs AJ; Mol SJ; Mulder PG
    Thorax; 1999 Mar; 54(3):207-12. PubMed ID: 10325895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD.
    Siler TM; Nagai A; Scott-Wilson CA; Midwinter DA; Crim C
    Respir Med; 2017 Feb; 123():8-17. PubMed ID: 28137501
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative efficacy and safety of twice daily fluticasone propionate powder versus placebo in the treatment of moderate asthma.
    Pearlman DS; Noonan MJ; Tashkin DP; Goldstein MF; Hamedani AG; Kellerman DJ; Schaberg A
    Ann Allergy Asthma Immunol; 1997 Apr; 78(4):356-62. PubMed ID: 9109702
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study.
    Murray CS; Woodcock A; Langley SJ; Morris J; Custovic A;
    Lancet; 2006 Aug; 368(9537):754-62. PubMed ID: 16935686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
    Wouters EF; Postma DS; Fokkens B; Hop WC; Prins J; Kuipers AF; Pasma HR; Hensing CA; Creutzberg EC;
    Thorax; 2005 Jun; 60(6):480-7. PubMed ID: 15923248
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety profile of fluticasone furoate administered once daily in the morning or evening: a randomized, double-blind, double-dummy, placebo-controlled trial in adult and adolescent patients with persistent bronchial asthma.
    Medley H; Orozco S; Allen A
    Clin Ther; 2012 Aug; 34(8):1683-95. PubMed ID: 22796247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study.
    Brutsche MH; Brutsche IC; Munawar M; Langley SJ; Masterson CM; Daley-Yates PT; Brown R; Custovic A; Woodcock A
    Lancet; 2000 Aug; 356(9229):556-61. PubMed ID: 10950233
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose-ranging study of fluticasone propionate administered once daily via multidose powder inhaler to patients with moderate asthma.
    Nathan RA; Li JT; Finn A; Jones R; Payne JE; Wolford JP; Harding SM
    Chest; 2000 Aug; 118(2):296-302. PubMed ID: 10936116
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study.
    Noonan MJ; Chervinsky P; Wolfe J; Liddle R; Kellerman DJ; Crescenzi KL
    J Asthma; 1998; 35(2):153-64. PubMed ID: 9576141
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.